Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53705, USA.
Department of Structural Biology, Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
Eur J Med Chem. 2023 Oct 5;258:115567. doi: 10.1016/j.ejmech.2023.115567. Epub 2023 Jun 20.
Molecular glues, functioning via inducing degradation of the target protein while having similar molecular weight as traditional small molecule drugs, are emerging as a promising modality for the development of therapeutic agents. However, the development of molecular glues is limited by the lack of general principles and systematic methods. Not surprisingly, most molecular glues have been identified serendipitously or through phenotypic screening of large libraries. However, the preparation of large and diverse molecular glue libraries is not an easy task and requires extensive resources. We previously developed platforms for rapid synthesis of proteolysis targeting chimeras (PROTACs) that can be used directly for biological screening with minimal resources. Herein, we report a platform of rapid synthesis of molecular glues (Rapid-Glue) via a micromolar scale coupling reaction between hydrazide motif on the E3 ligase ligands and commercially available aldehydes with diverse structures. A pilot library of 1520 compounds is generated under miniaturized conditions in a high throughput manner without any further manipulation including purification after the synthesis. Through this platform, we identified two highly selective GSPT1 molecular glues through direct screening in cell-based assays. Three additional analogues were prepared from readily available starting materials by replacing the hydrolytic labile acylhydrazone linker with a more stable amide linker based on the two hits. All three analogues showed significant GSPT1 degradation activity and two of them possess comparable activity to the corresponding hit. The feasibility of our strategy is thus verified. Further studies by increasing the diversity and size of the library followed by appropriate assays will likely yield distinct molecular glues targeting novel neo-substrates.
分子胶水通过诱导靶蛋白降解而发挥作用,其分子量与传统小分子药物相似,是开发治疗药物的一种很有前途的方式。然而,分子胶水的发展受到缺乏通用原则和系统方法的限制。毫不奇怪,大多数分子胶水都是偶然发现的,或者是通过对大型文库进行表型筛选发现的。然而,制备大型多样的分子胶水库并非易事,需要大量资源。我们之前开发了用于快速合成蛋白水解靶向嵌合体(PROTAC)的平台,这些嵌合体可以直接用于生物筛选,只需很少的资源。在此,我们报告了一种通过在 E3 连接酶配体上的酰肼基与具有各种结构的商业醛之间进行毫摩尔规模的偶联反应来快速合成分子胶水(Rapid-Glue)的平台。在微型化条件下,以高通量方式生成了 1520 个化合物的先导文库,在合成后无需进行任何进一步的操作,包括纯化。通过该平台,我们通过在基于细胞的测定中直接筛选,鉴定了两种高度选择性的 GSPT1 分子胶水。基于这两个命中物,通过用更稳定的酰胺键替换易水解的酰腙键,从易得的起始原料制备了另外三个类似物。所有三个类似物均显示出显著的 GSPT1 降解活性,其中两个类似物的活性与相应的命中物相当。因此,我们的策略是可行的。通过增加文库的多样性和规模,并进行适当的测定,进一步研究可能会产生针对新型新底物的独特分子胶水。